Global Metformin Hydrochloride Sustained-release Tablets Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Metformin Hydrochloride Sustained-release Tablets Market Research Report 2024
Metformin hydrochloride sustained-release tablet is a medication used to treat type 2 diabetes. It is a long-acting form of metformin, which helps to lower blood sugar levels by decreasing the amount of glucose produced by the liver and increasing the body's sensitivity to insulin.
According to Mr Accuracy reports’s new survey, global Metformin Hydrochloride Sustained-release Tablets market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Metformin Hydrochloride Sustained-release Tablets market research.
Key manufacturers engaged in the Metformin Hydrochloride Sustained-release Tablets industry include Merck, Viatris, Apotex, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Qingdao Huanghai Pharmaceutical, CTTQ and Shanghai Pharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Metformin Hydrochloride Sustained-release Tablets were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Metformin Hydrochloride Sustained-release Tablets market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Metformin Hydrochloride Sustained-release Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Merck
Viatris
Apotex
Teva Pharmaceuticals
Sun Pharmaceutical Industries
Dr. Reddy's Laboratories
Qingdao Huanghai Pharmaceutical
CTTQ
Shanghai Pharmaceuticals
Tianan Pharmaceutical
Chongqing Conquer Pharmaceutical
CSPC
Jingfeng Pharmaceutical Group
Topfond Pharmaceutical
SinocorpPharma
Jiangsu Deyuan Pharmaceutical
Segment by Type
0.5g
0.25g
Hospital
Clinic
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Metformin Hydrochloride Sustained-release Tablets report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Metformin Hydrochloride Sustained-release Tablets market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Metformin Hydrochloride Sustained-release Tablets market research.
Key manufacturers engaged in the Metformin Hydrochloride Sustained-release Tablets industry include Merck, Viatris, Apotex, Teva Pharmaceuticals, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Qingdao Huanghai Pharmaceutical, CTTQ and Shanghai Pharmaceuticals, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Metformin Hydrochloride Sustained-release Tablets were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Metformin Hydrochloride Sustained-release Tablets market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Metformin Hydrochloride Sustained-release Tablets market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
Viatris
Apotex
Teva Pharmaceuticals
Sun Pharmaceutical Industries
Dr. Reddy's Laboratories
Qingdao Huanghai Pharmaceutical
CTTQ
Shanghai Pharmaceuticals
Tianan Pharmaceutical
Chongqing Conquer Pharmaceutical
CSPC
Jingfeng Pharmaceutical Group
Topfond Pharmaceutical
SinocorpPharma
Jiangsu Deyuan Pharmaceutical
Segment by Type
0.5g
0.25g
Segment by Application
Hospital
Clinic
Other
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Metformin Hydrochloride Sustained-release Tablets report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices